Aditya Bardia

Aditya Bardia's AcademicInfluence.com Rankings

Aditya Bardia

Engineering

#6134

World Rank

#7441

Historical Rank

Biomedical Engineering

#516

World Rank

#526

Historical Rank

Applied Physics

#1915

World Rank

#1949

Historical Rank

engineering Degrees

Download Badge

Engineering

Aditya Bardia's Degrees

Bachelors Biomedical Engineering Stanford University

Why Is Aditya Bardia Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Aditya Bardia's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (2013) (1854)
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis (2014) (1786)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells (2013) (938)
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility (2014) (789)
A microfluidic device for label-free, physical capture of circulating tumor cell-clusters (2015) (568)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. (2019) (527)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. (2018) (518)
Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. (2007) (444)
Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer (2019) (427)
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models (2018) (316)
HER2 expression identifies dynamic functional states within circulating breast cancer cells (2016) (304)
Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. (2006) (299)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. (2021) (297)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. (2016) (241)
Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. (2006) (229)
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis (2020) (226)
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer (2017) (224)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer (2019) (204)
Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. (2008) (172)
Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. (2015) (160)
Diagnosis of obesity by primary care physicians and impact on obesity management. (2007) (154)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future (2020) (153)
Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis (2020) (144)
Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. (2007) (141)
Tunable Nanostructured Coating for the Capture and Selective Release of Viable Circulating Tumor Cells (2015) (141)
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors (2017) (133)
Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. (2007) (132)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. (2017) (128)
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics (2017) (119)
PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. (2019) (113)
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions (2019) (104)
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations (2017) (102)
Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. (2006) (101)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. (2017) (99)
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. (2016) (99)
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. (2017) (92)
Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. (2007) (90)
Using machine learning to parse breast pathology reports (2016) (90)
Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study (2011) (88)
Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells (2021) (81)
Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. (2021) (80)
Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer (2013) (79)
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (78)
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. (2017) (77)
Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial. (2021) (76)
Circulating tumor cells exhibit metastatic tropism and reveal brain metastasis drivers. (2019) (74)
Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. (2009) (73)
Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. (2016) (73)
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. (2018) (67)
Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. (2019) (66)
Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial. (2020) (65)
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (2019) (65)
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. (2018) (62)
Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments (2017) (61)
Novel antibody–drug conjugates for triple negative breast cancer (2020) (59)
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. (2014) (58)
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. (2019) (56)
Body Size and Incident Colorectal Cancer: A Prospective Study of Older Women (2010) (55)
Relative Weight at Age 12 and Risk of Postmenopausal Breast Cancer (2008) (54)
LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) (2020) (53)
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer (2021) (51)
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study (2021) (51)
18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials (2016) (51)
Pharmacodynamic study of Disulfiram in Men with Non-metastatic Recurrent Prostate Cancer (2013) (50)
Patient‐reported outcomes in women with breast cancer enrolled in a dual‐center, double‐blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor‐induced musculoskeletal symptoms (2014) (48)
Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial (2018) (48)
AR Expression in Breast Cancer CTCs Associates with Bone Metastases (2018) (46)
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies (2021) (46)
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. (2021) (45)
Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. (2018) (44)
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations (2019) (44)
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer (2021) (42)
Publication bias for CAM trials in the highest impact factor medicine journals is partly due to geographical bias. (2007) (42)
Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis (2009) (41)
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer (2019) (40)
Abstract GS2-03: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients (2019) (40)
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial (2022) (38)
Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC). (2018) (38)
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. (2020) (37)
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. (2019) (37)
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. (2019) (35)
Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. (2013) (34)
Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances (2018) (33)
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors. (2018) (33)
Mediastinal pancreatic pseudocyst with acute airway obstruction (2007) (32)
Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. (2011) (30)
HER 2 expression identifies dynamic functional states within circulating breast cancer cells (2016) (30)
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer (2018) (30)
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy (2020) (30)
Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. (2020) (29)
Declining sex ratio: role of society, technology and government regulation in Faridabad district, Haryana. (2004) (28)
Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. (2019) (28)
Non-azotemic refractory rickets in Indian children. (2005) (28)
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. (2017) (28)
Long-term outcome in children with primary distal renal tubular acidosis. (2005) (27)
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors (2020) (27)
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer (2021) (27)
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. (2021) (26)
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) (2020) (26)
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial (2021) (25)
Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. (2010) (25)
Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology (2017) (25)
Treatment of obesity. (2007) (25)
A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). (2019) (25)
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) (2021) (25)
Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. (2014) (24)
Prognostic web‐based models for stage II and III colon cancer (2011) (24)
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial). (2020) (23)
Relationship of established risk factors with breast cancer subtypes (2021) (23)
Is a solitary inguinal lymph node metastasis from adenocarcinoma of the rectum really a metastasis? (2010) (23)
Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. (2008) (22)
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (2022) (22)
Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer? (2014) (22)
Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). (2017) (22)
Precision medicine and personalized breast cancer: combination pertuzumab therapy (2014) (22)
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. (2019) (21)
Tinnitus and Hyperacusis (2009) (21)
LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) (2022) (20)
A careful reassessment of anthracycline use in curable breast cancer (2021) (20)
Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer (2018) (20)
Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC). (2021) (19)
858PSacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results (2017) (19)
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer (2017) (19)
Gene-Expression-Based Predictors for Breast Cancer (2015) (19)
Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer (2016) (19)
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance (2020) (19)
Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC). (2018) (18)
Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results (2018) (18)
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis (2021) (18)
Abstract 1439: Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: systematic review and meta-analyses of over 18,000 patients (2016) (18)
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. (2020) (18)
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer (2019) (18)
Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. (2016) (17)
Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities. (2021) (17)
Optimizing Radiotherapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. (2020) (16)
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital (2016) (16)
Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (2021) (16)
Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). (2021) (16)
Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer (2015) (16)
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer (2021) (15)
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. (2020) (15)
Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC) (2018) (15)
Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01. (2017) (15)
Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study (2022) (15)
Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer (2021) (15)
Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy (2021) (14)
Spinal intradural extraosseous Ewing's sarcoma (2011) (14)
Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study. (2020) (14)
211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study (2022) (14)
Personalizing cardiovascular disease prevention among breast cancer survivors (2012) (14)
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer (2021) (14)
The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: From Enumeration to Molecular Characterization (2014) (14)
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer (2020) (13)
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic (2020) (13)
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial (2018) (13)
Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC) (2013) (13)
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC). (2015) (12)
Temporal trends and outcomes among patients admitted for immune-related adverse events: A single-center retrospective cohort study from 2011-2018. (2021) (12)
Clinical Validation of a Cell-Free DNA Gene Panel. (2019) (12)
Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. (2021) (12)
AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). (2021) (12)
Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer (2017) (12)
Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer (2013) (12)
LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study (2021) (12)
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer (2022) (11)
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities. (2021) (11)
Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. (2015) (11)
Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts (2020) (11)
Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC). (2016) (10)
Abstract P6-18-06: Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials (2019) (10)
Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7. (2015) (10)
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer (2018) (10)
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role (2022) (10)
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial. (2022) (10)
High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. (2017) (10)
Pilot evaluation of aprepitant for the treatment of hot flashes. (2006) (10)
Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer (2017) (10)
Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib (2021) (10)
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types (2021) (9)
Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (2020) (9)
KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). (2020) (9)
Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer (2020) (9)
Search Strategies for Retrieving Complementary and Alternative Medicine Clinical Trials in Oncology (2006) (9)
Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready? (2018) (9)
Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC). (2020) (9)
LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial (2021) (9)
Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC (2016) (9)
Abstract OT-03-09: Trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator’s choice of chemotherapy in patients with hormone receptor-positive (HR+), HER2 low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: A randomized, global phase 3 trial (DES (2021) (9)
Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer. (2017) (9)
Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC). (2016) (8)
Dietary supplement usage by patients with cancer undergoing chemotherapy: does prognosis or cancer symptoms predict usage? (2007) (8)
Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer (2019) (8)
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer (2022) (8)
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009). (2018) (8)
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer (2020) (8)
Phase II study of ruxolitinib , a selective JAK 1 / 2 inhibitor , in patients with metastatic triple-negative breast cancer (2018) (8)
Personalized Tamoxifen: A Step Closer but Miles To Go (2010) (8)
Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center (2021) (7)
Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (2020) (7)
Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer (2021) (7)
POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. (2020) (7)
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer (2018) (7)
Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). (2020) (7)
Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. (2022) (7)
Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers. (2015) (7)
Levetiracetam for the treatment of hot flashes: a phase II study (2007) (7)
Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. (2020) (7)
KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer. (2019) (7)
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer (2021) (7)
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (7)
Validation of target engagement using 18F-fluoroestradiol PET in patients undergoing therapy with selective estrogen receptor degrader, ARN-810 (GDC-0810) (2015) (7)
Abstract PD1-13: Somatic BRCA mutation detection by circulating tumor DNA analysis in patients with metastatic breast cancer: Incidence and association with tumor genotyping results, germline BRCA mutation status, and clinical outcomes (2018) (7)
Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC) (2022) (6)
Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC). (2021) (6)
214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study (2022) (6)
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results (2022) (6)
Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan (2022) (6)
Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132). (2016) (6)
Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC). (2021) (6)
Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA (2021) (6)
Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). (2021) (6)
Abstract CT107: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Efficacy and safety results from phase II of the TRINITI-1 study (2018) (6)
Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. (2019) (6)
Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR) (2021) (6)
Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial (2019) (6)
Abstract OT2-07-06: Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009) (2018) (5)
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors (2022) (5)
Phase II study of ruxolitinib in patients with pStat3+ breast cancer. (2013) (5)
Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. (2019) (5)
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low). (2022) (5)
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy (2019) (5)
Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience. (2015) (5)
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. (2021) (5)
257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2021) (5)
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. (2021) (5)
Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer. (2019) (5)
Mechanism of Action and Clinical Impact of Ribociclib—Response (2017) (5)
FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer. (2017) (5)
Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results. (2016) (5)
500 Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2− advanced/metastatic breast cancer: results from a Phase Ib clinical trial (2014) (5)
Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? (2019) (5)
Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting (2023) (5)
Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer (2021) (5)
Scarring moxibustion and religious scarification resulting in hepatitis C and hepatocellular carcinoma (2006) (5)
Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2017) (4)
Abstract A75: Circulating tumor cells in human breast cancer exhibit dynamic changes in epithelial and mesenchymal composition (2013) (4)
331P Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7 (2020) (4)
Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009; NCT02684032). (2017) (4)
Abstract P2-11-01: Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC) (2019) (4)
Antibody-drug conjugates in breast cancer. (2017) (4)
Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis. (2018) (4)
A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2. (2017) (4)
Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC) (2022) (4)
168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study (2022) (4)
Abstract PD2-08: Ribociclib with endocrine therapy for premenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer: Biomarker analyses from the phase III randomized MONALEESA-7 trial (2019) (4)
Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132). (2017) (4)
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID‐19 (2021) (4)
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer (2020) (4)
Abstract OT2-07-05: A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC) (2018) (4)
Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance. (2018) (4)
In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial. (2019) (4)
Abstract PS11-09: Impact ofUGT1A1status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer (2021) (4)
Abstract P6-18-04: Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis (2019) (4)
LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. (2016) (4)
Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552) (2015) (4)
Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. (2022) (4)
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (4)
276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC) (2020) (4)
Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. (2015) (4)
The Art of Oncology: COVID‐19 Era (2020) (4)
A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). (2013) (4)
Abstract P2-08-04: Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC) (2017) (4)
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer (2020) (4)
Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials (2019) (3)
Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2. (2022) (3)
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (3)
264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) (2021) (3)
Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. (2018) (3)
Locally recurrent secretory carcinoma of the breast. (2021) (3)
Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS (2019) (3)
233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) (3)
Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive (ER+), HER2- breast cancer (2015) (3)
Abstract CT064: Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience (2016) (3)
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. (2022) (3)
Reconstructing tumor trajectories during therapy through integration of multiple measurement modalities (2021) (3)
Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer (2019) (3)
A systematic literature review of the clinical prognosis of HR+/HER2- advanced or metastatic breast cancer with and without PIK3CA mutation. (2018) (3)
Bizarre big belly ball: intraabdominal abscess mimicking stauffer syndrome secondary to uterine leiomyosarcoma. (2007) (3)
Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy (2010) (3)
Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study. (2010) (3)
Localised prostate cancer - What the medical oncologist needs to know (2011) (3)
Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience. (2018) (3)
144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study (2022) (3)
Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC) (2020) (3)
Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD) (2019) (3)
Impact of PIK3CA tumor mutation on the association of aspirin or NSAID use and time to breast cancer recurrence. (2017) (3)
Abstract P5-13-02: Neoadjuvant endocrine therapy for estrogen receptor (ER) positive breast cancer: Comprehensive systematic review and meta-analysis (2016) (3)
Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study (2022) (3)
277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study (2020) (3)
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial. (2022) (2)
Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results (2015) (2)
EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy. (2019) (2)
Abstract PD13-02: Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer (2022) (2)
Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA. (2019) (2)
Cancer-Associated Neuropathic Pain and Paraneoplastic Syndromes (2012) (2)
Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer. (2019) (2)
Abstract OT2-03-03: Evaluation of talazoparib, a PARP inhibitor, in patients with somaticBRCAmutant metastatic breast cancer: Genotyping based clinical trial (2020) (2)
Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization (2022) (2)
Abstract P4-22-15: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results (2017) (2)
Physical activity and risk of postmenopausal breast cancer defined by hormone receptor status and histology: A large prospective cohort study with 18 years of follow up. (2006) (2)
Pharmacogenomics of Tamoxifen: Ready for Prime Time? (2010) (2)
66-year-old woman with painless vesicular lesions. (2009) (2)
Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial. (2017) (2)
Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER). (2020) (2)
Abstract P6-18-39: Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2- breast cancer (2019) (2)
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer (2022) (2)
Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation (2022) (2)
Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results (2015) (2)
1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC) (2022) (2)
Abstract OT3-05-03: POLARIS: Palbociclib (P) in hormone receptor-positive (HR+) advanced breast cancer: A prospective multicenter noninterventional study (2018) (2)
First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study. (2018) (2)
Antibody drug conjugates for patients with breast cancer. (2021) (2)
Abstract CT069: Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2- advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane (2018) (2)
Abstract CT110: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer following progression on a CDK4/6 inhibitor: Safety, tolerability, and pharmacokinetic results from Phase 1 of TRINITI-1 study (2017) (2)
Ribociclib Plus Endocrine Therapy in Premenopausal Women (2018) (2)
Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor (2017) (2)
Images in clinical medicine. Intratracheal melanoma metastases. (2006) (2)
Abstract P1-13-03: Association of PIK3CA mutation with clinical response to specific endocrine therapies in metastatic hormone receptor positive (HR+) breast cancer (2015) (2)
Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial (2022) (2)
P4-12-13: A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors: First Interim Analysis. (2011) (2)
Abstract OT3-05-06: EarLEE-2: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), intermediate-risk, early breast cancer (EBC) (2018) (2)
Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer. (2018) (2)
179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy (2020) (2)
Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. (2017) (2)
O3.1Targeting the estrogen receptor: old receptor, new drug(s) (2015) (2)
Abstract LB-C16: Safety and tumor responses of the anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in refractory, metastatic, triple-negative breast cancer (TNBC): An ongoing Phase II trial (2015) (2)
Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial (2018) (2)
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer (2022) (2)
Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion (2021) (2)
Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC). (2019) (2)
Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). (2021) (2)
Abstract P1-19-06: Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer (2020) (2)
Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study. (2020) (2)
Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer (2022) (2)
Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC). (2022) (2)
Sacituzumab Govitecan in Metastatic Breast Cancer. Reply. (2021) (2)
Digoxin as an inhibitor of global hypoxia inducible factor-1α (HIF1α) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial. (2013) (2)
Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer (2022) (1)
Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2–breast cancer (2019) (1)
A closer look at sacituzumab govitecan-hziy. (2020) (1)
Triplet Combination of Endocrine Therapy with CDK 4/6 Inhibitor, Ribociclib, and MTOR Inhibitor, Everolimus in HR+, HER2-ABC: Results from the Dose-Expansion Cohort (2017) (1)
Abstract OT2-08-01: A phase 1b trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy with/without CDK 4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC) (2020) (1)
Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors (2017) (1)
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series (2022) (1)
Flu vaccination rate of patients with severe immune-related adverse events. (2019) (1)
Elacestrant may improve outcomes for patients whose metastatic breast cancers progressed on prior endocrine therapy (2022) (1)
Abstract P6-10-03: Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study (2023) (1)
Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer. (2020) (1)
Abstract P2-02-18: Higher mutation burden and mutant allele fraction of circulating tumor DNA corresponds to worse progression free survival in metastatic breast cancer patients (2018) (1)
SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis? (2017) (1)
Sex ratio in India (2006) (1)
Abstract CT087: Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations (2017) (1)
Association of angiotensin II blockers with survival among men with prostate cancer: Results from CaPSURE. (2011) (1)
A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial. (2014) (1)
Abstract PL06-04: Molecular characterization of circulating tumor cells. (2013) (1)
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population (2020) (1)
Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1 (2022) (1)
Does efficacy of non-estrogenic therapies for hot flashes among women vary by breast cancer history and tamoxifen use? A pooled analysis (2008) (1)
Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors (2021) (1)
Abstract P4-01-06: Elacestrant (RAD1901) inhibits growth of ex vivo cultured circulating tumor cells derived from hormone receptor-positive metastatic breast cancer (mBC) patients including those harboring ESR1 mutations (2020) (1)
356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009 (2020) (1)
Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC) (2022) (1)
1977 Synergy of LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), with paclitaxel in a gene expression signature-enriched cohort of triple-negative breast cancer (TNBC) (2015) (1)
Abstract PD13-07: PD13-07 Combination therapy with the AKT inhibitor, ipatasertib, endocrine therapy, and a CDK4/6 inhibitor for hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC): results from the phase I TAKTIC trial (2023) (1)
Abstract P5-23-04: Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor (2018) (1)
KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer (2019) (1)
Phase II multicenter study of talazoparib for somatic BRCA1/2 mutant metastatic breast cancer. (2021) (1)
Abstract CT141: Genetic landscape of premenopausal HR+/HER2- advanced breast cancer (ABC) based on comprehensive circulating tumor DNA analysis and association with clinical outcomes in the Phase III MONALEESA-7 trial (2019) (1)
Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer. (2013) (1)
358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer (2020) (1)
Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer. (2018) (1)
Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC). (2021) (1)
persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC). (2021) (1)
Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). (2009) (1)
Persistence of AKT1 low quiescent cancer cells after neoadjuvant chemotherapy in triple negative breast cancer patients. (2017) (1)
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer (2021) (1)
Abstract OT3-02-06: Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial (2017) (1)
Research Biopsies: An integrative review of the experiences of patients with cancer (2018) (1)
Abstract P1-12-03: Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer (2017) (1)
Abstract P5-11-07: Real-world predictors of first-line treatment and descriptive outcomes in HR+/HER2−metastatic breast cancer patients in the US (2020) (1)
Abstract PS5-10:Esr1mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr+) metastatic breast cancer (mbc): A translational investigation (2021) (1)
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer. (2022) (1)
ABSTRACTS 32nd Annual Meeting • American Society of Preventive Oncology, Bethesda, Maryland • March 16-18, 2008 (2008) (1)
Abstract P4-10-09: Patient-centered dosing: Oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC) (2022) (1)
Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting. (2019) (1)
Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis. (2018) (1)
Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib (2022) (1)
91O Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: Additional results and key subgroup findings (2021) (1)
Intratracheal Melanoma Metastases (2006) (1)
Abstract P4-20-07: Research biopsies in oncology-patient willingness, perceptions, understanding, and experience: An integrative review (2017) (1)
Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases. (2020) (1)
Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies. (2021) (1)
Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2) (2020) (1)
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network (2022) (1)
Mechanisms of Resistance to Antibody–Drug Conjugates (2023) (1)
Adjuvant abemaciclib for high-risk breast cancer: the story continues. (2021) (1)
Emre Ozkumur Sorting of Rare Circulating Tumor Cells Independent − Dependent and − Inertial Focusing for Tumor Antigen (2013) (1)
Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies (2022) (1)
Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes. (2018) (1)
Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer (2018) (1)
Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition. (2021) (1)
Trastuzumab for small HER-2+ breast cancer: small tumor, big decision. (2012) (1)
AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer. (2021) (1)
Abstract P2-14-17: A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC) (2022) (1)
220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD (2022) (1)
Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS). (2021) (1)
Abstract PD13-08: PD13-08 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC) (2023) (1)
Abstract P4-10-15:PIK3CAmutational analysis using cell-free DNA next-generation sequencing detects activating mutations that may be missed with targeted hot-spot testing (2020) (1)
Efficacy and Safety of Self Expanding Metal Stents (SEMS) in Alleviating Combined Malignant Biliary and Duodenal Obstruction: A Nine Year Tertiary Center Experience (2006) (1)
Abstract 1903: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Ká inhibitors in breast cancer (2020) (1)
Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA). (2021) (1)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer (2019) (0)
Abstract PD13-04: PD13-04 Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy for previously treated, estrogen receptor+, HER2– advanced breast cancer (2023) (0)
P01.02 Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study (2021) (0)
Acknowledgement of reviewers 2015 (2016) (0)
Chabner Colloquium: Answering the Big Questions in Cancer Research & 2017 STO Annual Meeting (2017) (0)
P-162Interim Results of IMMU-132 (Sacituzumab Govitecan), an Anti-Trop-2 Antibody-Drug Conjugate (ADC), in Patients (pts) with Metastatic Gastrointestinal (GI) Cancers (2015) (0)
Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS) (2022) (0)
Decision-Analytic Modeling Studies: An Overview for Clinicians Using Dlbcl As An Example. (2015) (0)
Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC) (2022) (0)
Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer (2022) (0)
Adult Weight Gain and Risk of Developing Non-Hodgkin Lymphoma (NHL): Results from a Large Prospective Cohort Study of Older Women. (2006) (0)
1629OA systematic rapid autopsy program tracks temporal and spatial heterogeneity of human tumors and identifies mechanisms of resistance to targeted therapies (2017) (0)
Acknowledgement of reviewers 2014 (2014) (0)
Abstract HER2-19: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score </25 randomized to endocrine therapy +/- chemotherapy: results from SWOG S1007 (RxPONDER) (2023) (0)
Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer. (2023) (0)
Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer (2021) (0)
Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer (2022) (0)
Mipomersen For Treatment Of Hypercholesteremia: Evidence Review And Meta Analytic Evaluation Of Randomized Controlled Trials (2015) (0)
Abstract PD17-03: Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib for localized HR+/HER2- breast cancer (LEADER) (2023) (0)
Abstract PD5-08: Not presented (2018) (0)
Abstract OT1-03-04: Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01 (2023) (0)
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer (2017) (0)
Reply to R. Nishihara et al. (2022) (0)
Abstract PD9-06: Paired pre- and post-treatment DNA sequencing identifies genomic alterations mediating clinical resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer (2019) (0)
Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials (2023) (0)
Abstract P1-12-01: Withdrawn (2018) (0)
Abstract 1736: A novel RNA-based assay for the detection and monitoring of circulating tumor cell signatures in breast cancer (2017) (0)
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types (2021) (0)
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply. (2019) (0)
Obesity and Obesity Management Not Being Documeented (2008) (0)
Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting. (2018) (0)
Changes in patient-reported outcomes in women with breast cancer in a multicenter double-blind randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms (AIMSS). (2012) (0)
Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer. (2012) (0)
Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer (2013) (0)
Abstract P3-14-02: Upper extremity edema in the at-risk arm among patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer (2019) (0)
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2. (2022) (0)
Abstract OT1-07-05: TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) (2020) (0)
Abstract P1-13-07: Investigating NF1 Mutations in Circulating Tumor DNA of Patients with Hormone-receptor Positive (HR+) Breast Tumors Resistant to CDK4/6 Inhibition (CDK4/6i): A Retrospective Clinical Analysis (2023) (0)
Abstract P2-05-11: Not presented (2018) (0)
Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors (2022) (0)
Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC). (2013) (0)
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. (2023) (0)
Abstract P4-03-04: Dynamic tomographic optical breast imaging (TOBI) for neoadjuvant chemotherapy monitoring (2016) (0)
Abstract 960: Overlapping expression landscape of antibody drug conjugate targets, trophoblast cell surface antigen 2 (Trop-2) & human epidermal growth factor receptor 2 (HER2), in breast cancer (2023) (0)
Progress in the treatment of breast cancer: increased survival, improved patient experience, and advances in drug formulation. (2023) (0)
Levetiracetam for the treatment of hot flashes: A pilot study (2007) (0)
Abstract PD13-02: PD13-02 Exploratory gene expression analysis of coopERA Breast Cancer (BC): a study evaluating neoadjuvant giredestrant versus anastrozole alone and in combination with palbociclib in ER-positive, HER2-negative untreated early BC (2023) (0)
Abstract CT517: Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2- advanced breast cancer (aBC): combined biomarker analyses from a Phase 1/2 study in postmenopausal women and a Phase 1 study in postmenopausal Japanese women (2022) (0)
Patient attitudes towards biobanks and preferences for use of archived biospecimens. (2018) (0)
Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial (2019) (0)
Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC) (2023) (0)
Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS (2023) (0)
Chabner Colloquium: Answering the Big Questions in Cancer Research & 2018 STO Annual Meeting (2018) (0)
Abstract PS7-02: The relationship of established breast cancer risk factors with breast cancer subtypes (2021) (0)
31st Annual Meeting • American Society of Preventive Oncology, Houston, Texas • March 2–4, 2007 (2007) (0)
Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study) (2023) (0)
Abstract 6744: Cell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: A multi-institutional analysis of incidence and clinical outcomes (2023) (0)
Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial (2022) (0)
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma (2023) (0)
Abstract 4353: Utilizing scRNA sequencing to understand biomarkers of response and resistance to Sacitizumab Govetican in localized TNBC (2023) (0)
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (0)
Pooled Analysis of Safety and Dose Reductions in the MONALEESA-2, -3, and -7 Phase III Trials on Ribociclib Plus Endocrine Therapy to Treat Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (2020) (0)
Abstract P4-01-42: Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 studies (2023) (0)
Utilizing Natural Language Processing (NLP) to identify breast cancer associated-lung metastases from pathology reports to delineate characteristics and challenges of this common site of breast cancer recurrence. (2022) (0)
116TiPMONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR + , HER2– advanced breast cancer (aBC) (2015) (0)
Case 8-2023: A 71-Year-Old Woman with Refractory Hemolytic Anemia. (2023) (0)
68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC (2020) (0)
274TiP Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01 (2022) (0)
Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53 (2023) (0)
Abstract P4-14-01: Whole exome sequencing reveals greater intratumor genetic heterogeneity in primary breast cancer arising in African American compared to Caucasian women (2015) (0)
A careful reassessment of anthracycline use in curable breast cancer (2021) (0)
Patient-centered dosing: oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC) (2022) (0)
Abstract CT073: Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: a translational investigation (2023) (0)
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. (2023) (0)
Abstract PD9-07: Genomic landscape of metastatic breast cancer (MBC): Comprehensive cell-free DNA analysis from over 10,000 patients and comparison with primary breast cancer (2021) (0)
Abstract P6-10-08:AKT1alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications (2020) (0)
Abstract PS18-18: Microsatellite instability high (MSI-H) detection utilizing targeted plasma based genotyping in metastatic breast cancer (2021) (0)
Can Physical Activity Reduce The Risk of Breast Cancer? (2007) (0)
Abstract P5-20-02: HER2 mutations detected by ctDNA in ER+/HER2- metastatic breast cancer patients: Incidence and impact on clinical outcomes (2018) (0)
Abstract P1-15-01: Withdrawn (2019) (0)
Abstract OT-09-06: Phase II neoadjuvant study of GDC-9545 + palbociclib (palbo) vs anastrozole (A) + palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC) (2021) (0)
Abstract PD14-04: Circulating tumor DNA characterization of invasive lobular carcinoma in patients with metastatic breast cancer (2022) (0)
Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis (2019) (0)
Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somaticBRCA1/2mutant metastatic breast cancer (2021) (0)
Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation (2022) (0)
Abstract OT1-04-05: Phase 1/2 dose-escalation and expansion study investigating SAR439859, a potent, oral, selective estrogen receptor degrader, +/- palbociclib in metastatic breast cancer (2020) (0)
Abstract 443: Blood-based genotyping and clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib in real-world settings: Results from POLARIS (2019) (0)
Limitations of “Evidence-Based Indications” for Herbs–Reply–I (2007) (0)
Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling (2022) (0)
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer (2022) (0)
Patient and disease characteristics of women with acute myelogenous leukemia (AML) and a history of breast cancer (BC). (2010) (0)
Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1) (2022) (0)
Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with ESR1 mutations and fusions (2022) (0)
Does antioxidant supplementation reduce primary cancer incidence and mortality?: Systematic review and meta analysis. (2006) (0)
OT1-01-01: Prospective Clinical Trial Evaluating Efficacy of Zoledronic Acid (ZA) Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial. (2011) (0)
258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC) (2021) (0)
Abstract OT1-12-05: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer (2022) (0)
Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer (2023) (0)
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models (2018) (0)
Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence. (2015) (0)
Cancer Pain Control with Traditional Chinese Medicine (2010) (0)
Abstract P4-01-14: Changes in the Genomic Spectrum of Actionable Alterations in HER2 Negative Metastatic Breast Cancer in Serial Cell Free DNA (cfDNA) Analysis (2023) (0)
Sex ratio in India [letter] (2006) (0)
Abstract P5-01-06: Cell-free DNA (cfDNA) analysis of ESR1-mutant advanced breast cancer (aBC): Impact of subsequent therapy on mutation persistence (2020) (0)
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison (2023) (0)
Clinical implementation of tumor genotyping to guide development of personalized regimens for patients with metastatic breast cancer: Challenges and opportunities (2016) (0)
Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials (2019) (0)
Acknowledgement of reviewers 2015 (2015) (0)
Volume 22 Acknowledgments (2017) (0)
Abstract P4-07-65: Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial (2023) (0)
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer (2023) (0)
A Phase I Study of Adjuvant Niraparib Administered Concurrently with Postoperative Radiation Therapy in Patients with Localized Triple Negative Breast Cancer (2022) (0)
Abstract P2-01-14: circulating tumor cells in breast cancer exhibit dynamic changes in epithelial and mesenchymal cell composition (2012) (0)
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer (2021) (0)
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy (2020) (0)
Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC) (2023) (0)
Abstract P5-21-10: Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative breast cancer (2018) (0)
Abstract LB033: Longitudinal ctDNA changes in patients with long-term response to palbociclib combination therapy for advanced breast cancer: A preliminary analysis from the real-world POLARIS study (2021) (0)
Abstract PD10-01: PD10-01 Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach (2023) (0)
Abstract P2-01-01: Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC) (2022) (0)
Limitations of evidence-based indications for herbs. Authors' reply (2007) (0)
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC). (2016) (0)
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis (2023) (0)
Abstract P2-14-19: Surgical and long-term outcomes of patients receiving neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer (2019) (0)
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (0)
Abstract P4-01-06: Comparison of tumor genotyping and cell-free circulating tumor DNA sequencing in metastatic breast cancer patients and their utility in the selection of matched therapy (2019) (0)
Abstract OT2-01-03: ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC) (2023) (0)
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. (2023) (0)
P416 EVALUATION OF THE ROLE OF CELLULAR ANTIOXIDANT ENZYMES IN HEPATITIS C VIRUS (HCV) REPLICATION (2014) (0)
Abstract OT2-11-03: AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-)PIK3CA-mutated advanced breast cancer (2022) (0)
Abstract 3173: AKT1lowquiescent cancer cells persist after neoadjuvant chemotherapy in triple-negative breast cancer patients (2017) (0)
Cost Effectiveness Of Statins In Primary Prevention Of Coronary Heart Disease: A Systematic Review And Quality Assessment Of Economic Evidence To Elucidate Recent Trends In Usa (2015) (0)
Abstract OT3-25-01: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial (2023) (0)
Abstract P1-05-05: Comparison of genotyping results from tissue and circulating DNA (ctDNA) in patients with metastatic breast cancer (2017) (0)
Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (2022) (0)
Impact of Tumour Genomics on Response to Standard Neo-adjuvant Chemotherapy in Triple-Negative Breast Cancer (2022) (0)
Abstract OT1-11-01: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping (2023) (0)
Abstract SP012: Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors (2021) (0)
Acknowledgement of reviewers 2019 (2020) (0)
Abstract P2-08-06: A phase 1 study of RAD1901, a novel, oral selective estrogen receptor degrader, for the treatment of ER-positive advanced breast cancer (2017) (0)
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. (2023) (0)
Abstract P3-09-11: Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer (2022) (0)
333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer (2021) (0)
Abstract PS18-19: Comparison of metastatic genomic profile in patients ≤45 years and patients >45 years with triple-negative breast cancer (2021) (0)
Second Medical Opinions in the Era of Personalized Medicine (2015) (0)
Abstract P5-16-07: Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy (2023) (0)
Abstract P5-11-02: Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (2020) (0)
275TiP ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC) (2022) (0)
Abstract P1-08-01: Virtual molecular and precision medicine (vMAP) clinic to improve access to clinical trials for patients with metastatic breast cancer: an academic-community collaboration (2023) (0)
Abstract IA18: Molecular signatures of circulating tumor cells (2020) (0)
Abstract P4-08-08: Genomic progression, detected by circulating tumor DNA (ctDNA) sequencing, as an early predictor of disease progression in metastatic breast cancer (MBC) (2019) (0)
Abstract 3023: Dissecting mechanisms of breast cancer metastasis through patient-derived circulating tumor cells (2018) (0)
Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials (2023) (0)
Abstract 962: Multiplexed mutational profiling of breast tumor as an efficient clinical tool for personalized breast cancer treatment (2012) (0)
Abstract P5-14-09: Comparison of cell-free DNA genomics of breast cancer associated-chest wall disease vs. age & subtype matched controls with metastatic breast cancer not involving the chest wall (2023) (0)
Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
Abstract P2-05-10: Withdrawn (2018) (0)
Risk of multiple primary melanomas. (2006) (0)
Abstract PD1-10: Impact of Race on Clinical, Socioeconomic, and Genomic Characteristics, Clinical Trial Participation, and Receipt of Genotype-matched Therapy Among Patients with Metastatic Breast Cancer (2023) (0)
Abstract SY30-01: Molecular characterization of single circulating tumor cells. (2013) (0)
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators. (2009) (0)
Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020: commentary. (2020) (0)
Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Using Dynamic Tomographic Optical Breast imaging (DTOBI) (2014) (0)
Abstract PD8-06: Attitudes towards use of archived biospecimens among patients with cancer (2018) (0)
Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020. (2020) (0)
Abstract P4-09-06: Brain metastases (BM) in patients with metastatic breast cancer (MBC) and circulating cell-free DNA (cfDNA) somaticBRCAmutations (2020) (0)
Abstract P5-16-16: Role of tumor microenvironment, as assessed by breast MRI background parenchymal enhancement (BPE), in modulating response to neoadjuvant chemotherapy in young women with localized breast cancer (2017) (0)
Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. (2022) (0)
Correlation of Triglycerides and Acute Pancreatitis: a Systematic Evidence Review. (2015) (0)
Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer (2019) (0)
Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer (2021) (0)
Abstract P5-01-05: Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2- advanced/metastatic breast cancer (2020) (0)
Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer (2023) (0)
Prochlorperazine and 5HT3 antagonists for the treatment of breakthrough chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. (2010) (0)
Abstract P5-13-06: Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax + fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-negative metastatic breast cancer (mBC) (2022) (0)
Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
Abstract LB-192: Circulating tumor cell clusters are precursors of breast cancer metastasis (2014) (0)
Abstract P6-17-35: Withdrawn (2019) (0)
Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis (2023) (0)
Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS (2022) (0)
Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App (2022) (0)
Abstract P1-06-03: Serial evolution of hormone receptor status and mutational profile among patients with metastatic breast cancer (2017) (0)
Abstract P6-10-10: Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan (2023) (0)
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (0)
Abstract P4-02-01: Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy using dynamic tomographic optical breast imaging (TOBI) (2013) (0)
Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) (2021) (0)
Abstract SY24-01: High-throughput CTC detection for noninvasive cancer monitoring (2017) (0)
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC). (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Aditya Bardia?

Aditya Bardia is affiliated with the following schools:

California Institute of Technology
University of California, San Diego
National Taiwan University
Baylor University
Massachusetts General Hospital
Duke University
Paris-Saclay University
Complutense University of Madrid
University of British Columbia
Vanderbilt University
Stanford University
Johns Hopkins University
Harvard University

Aditya Bardia's Academic­Influence.com Rankings

Aditya Bardia's Degrees

Why Is Aditya Bardia Influential?

Aditya Bardia's Published Works

Published Works

What Schools Are Affiliated With Aditya Bardia?

Aditya Bardia's AcademicInfluence.com Rankings